Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2003

View Archived Issues

Src kinase inhibitor protects mouse heart allografts

Raloxifene increases bone mineral density in Chinese women

Novel somatostatin sst2 agonists for anxiety, depression, etc. developed at Novartis

New antidepressant 5-HT receptor ligands covered by Ranbaxy patent

New orexin OX-1 antagonists, their preparation and use reported by GSK researchers

Novel cholecystokinin CCK2 antagonists and their use in gastrin-related disorders

New P2X7 receptor antagonists in early development at Pfizer

New NK1 receptor antagonists under study at Schering-Plough

Ortho-McNeil scientists prepare and test novel PDE5 inhibitors

Two series of ALK5 kinase inhibitors and their use described by GSK team

Ropinirole improves QOL in patients with restless legs syndrome

Pilot study suggests efficacy of rotigotine CDS in restless legs syndrome

Hepatobiliary tumors show encouraging response to rebeccamycin analogue in phase II trials

Positive interim data from phase II trial of Allovectin-7 reported at ASCO

News from ASCO: BMS-247550 active against breast cancer and NSCLC in phase II studies

In vitro study results for GCS-100 presented at ASCO industry sponsored satellite symposium

Ralfinamide displays excellent oral bioavailability in phase I studies

New approvals for Prempro

TheraCIM produces complete responses in head and neck cancer

Phase II SBIR grant supports discovery of novel antigens for HIV vaccines at VaxGen

HspE7 produces statistically significant results in RRP

Phase I/II trial to study CA4P plus chemotherapy in advanced ovarian cancer

MedImmune and Micromet to codevelop MT-103

Life Medical Sciences cleared to begin pivotal trial of Repel-CV

CT-2106 to advance into phase II trials

Cypress Bioscience revises milnacipran agreement with Pierre Fabre

AMG-162, a human MAb against RANKL, suppresses bone resorption in monkeys

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...